Optogenetics approaches, utilizing light-sensitive proteins, have emerged as unique experimental paradigms to modulate neuronal excitability. We aimed to evaluate whether a similar strategy could be used to control cardiac-tissue excitability.
Introduction
The continuous, efficient, and co-ordinated contraction of the heart is ensured through the hierarchical organization of its electrical conduction system. Abnormalities in the formation of the cardiac electrical signal or in its conduction may result in the appearance of abnormally slow heart rate, mechanical dyssynchrony, and even circulatory failure and death; fuelling a multi-billion dollar electronic pacemaker industry.
While becoming the treatment of choice for bradyarrhythmias and heart failure with ventricular dyssynchrony (cardiac resynchronization therapy, CRT), electronic pacemakers are not without limitations. These include the need for a surgical procedure with its associated risks, the requirement for repeated battery replacements, the inability to adjust heart rate in response to the body needs in the same effectiveness as the native pacemaker, and the resulting alteration in the normal activation of the heart that may have a deleterious effect on its contractile performance. 1 Similarly, CRT strategies are also limited with regard to the number and locations of pacing wires used due to anatomical constraints (coronary venous system distribution). The aforementioned limitations have consequentially motivated a decade-long search for alternative biological solutions for cardiac electrical pacemakers. 2 -4 The recent cloning of light-sensitive ion channels and their expression in mammalian cells 5 opened a new field in neuroscience; optogenetics. 6 -9 The most widely used protein in this emerging discipline has been Channelorhodopsin-2 (ChR2), a non-selective light-sensitive cationic channel initially identified in the green-alga Chlamydomonas.
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By expressing ChR2 or alternative light-sensitive channels in neuronal tissues, neuroscientist can now selectively sensitize distinct cell types to light, enabling the non-invasive activation, inhibition (using the hyperpolarizing light-sensitive chloride pump Halorhodopsin 11 or proton pump Archaerhodopsin 12 ), and modulation of specific neuronal populations in living animals with millisecond precision. 6 -9 Surprisingly, the use of optogenetics tools outside the brain has not been explored until recently. Initial proof-of-concept studies demonstrated the ability to affect cardiac excitability with ChR2. Arrenberg et al. expressed ChR2 and halorhodopsin (a light-sensitive chloride pump) in the zebrafish heart and were able to influence cardiac contraction rate. 13 Bruegmann et al. created a transgenic mouse embryonic stem cells and mice expressing ChR2 and demonstrated that cardiac pacing can be achieved also in vivo. 14 Jia et al. reported on the ability of using transfected HEK cells in vitro for cardiomyocyte pacing. 15 Finally, computational models were developed to model the effects of ChR2 expression and activation in the heart. 16 In the current work, we aimed to expand on these previous studies by utilizing cell grafts (NIH-3T3 fibroblasts) engineered to express the lightactivated ion channel ChR2 alone or together with the light-sensitive hyperpolarizing proton pump Archaerhodopsin-T (Arch-T). We then investigated whether these engineered cells can couple electrically with host cardiomyocytes in a co-culture model and specifically evaluated their ability to: (i) optogenetically pace the co-cultures in response to application of flashes of blue-light (activating ChR2) at varying frequencies; (ii) synchronize cardiac-tissue electrical activity in a model of conduction block; (iii) shorten the culture activation time by multisite optogenetics pacing; and (iv) suppress the culture electrical activity following activation of ArchT in response to continuous application of monochromatic red light.
Methods

Creation of the engineered ChR2-fibroblasts and ChR2/ArchT
The plasmid AAV-CAG-ChR2-GFP was obtained from Addgene. Stable transfection was achieved in NIH-3T3 fibroblasts with jetPEI TM transfection reagent (PolyPlus). The amount of jetPEI solution mixed with the plasmid DNA resulted in an N/P ratio of 5. Thus, 3 mg of DNA and 6 mL of jetPEI were added to each well (of a six-well plate) where the fibroblasts were seeded at 50 -70% confluence. Transfected cells were identified 48 h later and selected based on their fluorescence level by repeated fluorescenceactivated cell sorting. Cells were grown in modified Eagle's medium (MEM) supplemented with 10%-FCS, penicillin (100 U/mL), streptomycin (100 mg/mL), and 1% L-glutamine. To create the cells expressing both ArchT and ChR2, the ChR2-fibroblasts were transfected with the plasmid AAV-CAG-ArchT-dtTomato (Addgene) using the TransIT w -LT1 Transfection Reagent (MIR-2300; Mirus-Bio-LLC). ChR2/ArchT cells were then isolated by repeated FACS selection targeting cells with both green and red fluorescence.
Whole-cell patch-clamp recordings
Whole-cell recordings were conducted at room temperature from eGFP-expressing cells using MultiClamp700B and Digidata1440A (Axon-Instruments). The bath-solution contained (in mM): NaCl 140, KCl 3, HEPES 10, glucose 10, MgCl 2 2, and CaCl 2 2 (pH 7.4, adjusted with NaOH). The pipette solution contained (in mM): KCl 140, Na 2 ATP 10, EGTA 10, HEPES 5, CaCl 2 1, and MgCl 2 1 (pH 7.4, adjusted with KOH). Voltage-clamp recordings were performed from 2100 to +20 mV from a holding potential of 230 mV. Measurements were conducted in darkness or under LED illumination (470 nm, 2.61 mW/mm 2 ).
Preparation of the NRCMs monolayers and co-cultures
Primary cultures of 0-to 1-day-old neonatal rat (Sprague-Dawley) ventricular cardiomyocytes (NRCMs) were prepared as previously described. 17 The experimental protocol was approved by the Animal Study Committee of the Technion Faculty of Medicine. Briefly, cervical dislocation euthanasia was performed by a trained personal prior to harvesting of the cardiac tissue according to the American Veterinary Medical Association (AVMA) guidelines for the euthanasia of animals. The excised ventricular tissue was suspended in culture-medium (Ham F 10, 5% FCS, 5% horse serum, 100 U/mL penicillin, 100 mg/mL streptomycin; Biological-Industries, Beit-Haemek, Israel) and enzymatically dispersed with RDB (IIBR, Ness-Ziona, Israel). Following centrifugation, dispersed NRCMs were suspended in culturemedium and plated on microelectrode array (MEA) culture-plates, which were previously coated with fibronectin and seeded with (50 -100) × 10 3 ChR2-fibroblasts (or control non-transfected cells). The final ratio of cardiomyocytes to fibroblasts in these co-cultures was 5 -20:1. The cultures were treated with 5-bromo-2 ′ -deoxyuridine (BrdU) to reduce the proliferation of non-myocytes.
Creation of human embryonic stem cells-derived cardiomyocyte co-cultures
Undifferentiated human embryonic stem cells (hESC) (A 2 T 5 -clone) were propagated as described. 18, 19 To induce differentiation, hESC were cultivated in suspension for 7 -10 days as embryoid bodies (EBs). 18, 19 Beating areas, identified within the EBs following plating, were dissected and plated on the MEA plates. 20 One day later (5 -10) × 10 4 ChR2-fibroblasts were added to create the co-cultures.
Immunostainings
Co-cultures of eGFP-expressing ChR2-fibroblasts and NRCMs were grown at low density on gelatin-coated cover slips. Specimens were fixed with 4%-paraformaldehyde, permeabilized with 1% Triton X-100, blocked with 5% DHS, and incubated overnight at 48C with mouse anti-sarcomerica-actinin (Sigma, 1:100) and goat anti-connexin-43 (Cx43) (Santa-Cruz, 1:20) antibodies. The preparations were incubated with secondary antibodies (1:200, Jackson) and examined using confocal microscopy (Zeiss LSM-510-PASCAL).
Microelectrode array mapping
Extracellular recordings were performed using the MEA data-acquisition system (Multichannels-systems, Reutlingen, Germany). 20 The MEA system allows simultaneous recording from 60 to 252 electrodes at a high spatial (200 mm) and temporal (15 kHz) resolution. Local activation time (LAT) at each electrode was determined by the timing of the maximal negative deflection (2dV/dt max ) of the local electrogram. This information allowed the generation of color-coded activation maps using custom-written Matlabbased software.
Optogenetics illumination
Diffuse illumination of the NRCMs co-cultures was achieved with a 1000 W quartz tungsten halogen lamp (Newport Corporation), whereas focused illumination was performed using a high-power fibre-coupled 1.0 A monochromic LED (470 nm) connected to high-power LED driver (Thorlab). The former system was equipped with an electronic shutter, which was connected to a programmable stimulus-generator (STG-1004, multichannels systems) allowing the generation of flashes (50 ms long) at a frequency of 60-200 flashes/min. A monochromatic filter (470 + 10 nm, ChromaTechnology) was used for delivery of the monochromatic blue light. Dose-response curves were derived by altering flash duration (1 -50 ms) and light intensity (by changing the LED current-amplitude from 100 to 1000 mA, which translates to irradiance levels of 3.65-26.1 mW/mm 2 as measured at the tip of the optical fibre). A total of 16 consecutive flashes (rate: 50 flashes/min) were given at each set of parameters. Focused illumination (where the optical fibre was brought as close as possible to the region of interest within the co-culture) was performed in the majority of studies.
In some experiments (multisite optogenetics pacing and activation
Optogenetics cardiac pacing mapping to identify the source of the pacemaking activity), diffuse illumination of the entire culture was used. For activation of ArchT, a high-output 624 nm LED illumination system was used (Prizmatix, Israel), which was coupled with a 2 mm optical fibre. Continuous (30 s) illuminations were carried out during the MEA recordings.
Statistical analysis
Results are presented as mean + SEM. Distribution was evaluated for normality by the Shapiro-Wilk test. Matched pairs were compared using paired t-test.
Results
Voltage-clamp recordings from the engineered cells
A stable NIH-3T3 fibroblast line expressing the ChR2 transgene was established, propagated, and purified. Voltage clamp studies revealed negligible currents in the engineered cells in complete darkness ( Figure 1A, top) . In contrast, blue-light illumination (470 nm monochromatic light) induced a significant inward current ( Figure 1A , middle), which disappeared following termination of light exposure ( Figure 1A , bottom). The resulting current-voltage curve, displaying the average currents produced at different test potentials during blue-light exposure, is presented in Figure 1B . Notice the known inward rectification properties of the ChR2 channel and the slightly positive reversal potential. 21 We next changed the intensity of the stimulating light and noted an increase in the ChR2 current as function of illumination intensity ( Figure 1C) . Similarly, altering the duration of the illumination period significantly affected the recordings from the ChR2-fibroblasts. Figure 1D presents an example of the cumulative currents measured from an isolated ChR2-fibroblast, at different irradiance levels, as function of the illumination period. Figure 1E summarizes the mean cumulative charge in all cells studied (n ¼ 7) as function of the illumination duration. The reported values were adjusted to cell capacitance, and measurements were made at a holding potential of 2100 mV and irradiance level of 
mW/mm
2 . Note that increased flash duration was associated with increased cumulative charge density.
Optogenetics pacing in NRCMs co-cultures
To evaluate the feasibility of the proposed cell and gene therapy strategy as a 'biological-pacemaker' approach, we co-cultured the ChR2-fibroblasts (identified by their eGFP-fluorescence, Figure 2A and B) with primary cardiomyocyte cultures on top of MEA culture plates ( Figure 2A ). Immunostaining studies confirmed the development of gap junction between the NRCMs and the ChR2-fibroblasts (white punctuate Cx43 immunosignal in Figure 2B ). We then used focused illumination (programmed to emit predefined brief flashes of monochromatic blue light) to evaluate the ability of the engineered cells to pace the co-cultures at varying frequencies.
As shown in Supplementary data online, Movie S1, the ChR2-fibroblasts were able to reproducibly pace the NRCMs cultures in response to flashes of focused blue light. Importantly, we were able to vary the contraction rate of the cardiac-cultures by altering the frequency of the emitted light. Notice in the movie, the slow beating rate of the NRCMs at baseline and the resulting increase in the culture's contraction rate following illumination at 50, 100, and 150 flashes/min. This can also be appreciated in the MEA recordings ( Figure 2C ) showing a similar increase in action potential frequency in response to changes in the flashing rate (133-200 flashes/min in this example).
We next evaluated the efficiency of optogenetics pacing at different illumination rates. As summarized in Figure 3A , the mean percentage of captured beats exceeded 90% at focused illumination rates of ,100 flashes/min in all cultures studied (n ¼ 15). The percentage of captured beats gradually decreased at faster stimulation frequencies. For example, a stimulation rate of 70 flashes/min yielded contractions in 97 + 2% of the impulses, while the capturing efficiency decreased to 88 + 6% of all flashes at 130 flashes/min and to 56 + 8% at 200 flashes/min.
Interestingly, three types of co-cultures were identified with regard to their response to rapid stimulation ( Figure 3B ). In the 'high-responders' co-cultures (n ¼ 5), we observed capture of all beats at a stimulation rate of 170 flashes/min and .90% at a rate of 200 flashes/min. In the 'intermediate-responders' (n ¼ 5), we could still identify 100% capture at 130 flashes/min but this response decreased to 55% at 170 flashes/min. Finally, in the 'low-responders' (n ¼ 5), we observed 100% capture at a stimulation rate of 70 flashes/min, but capture frequency decreased to 70 and 45% at stimulation rates of 100 and 170 flashes/min, respectively.
We next performed dose-response studies focusing on the light intensity parameters (intensity and duration). Figure 3C shows the relationship between flash duration and capture efficiency. Notice that flash durations of .25 ms resulted in electrical capture .90% of all beats in the cultures studied (n ¼ 8). Shorter pulse durations resulted in a gradual decrease in capture frequency. A different type of dose-response relationship was observed when examining the effects of altering the intensity of the stimulating signal (irradiance level) on capture efficiency ( Figure 3D) . Interestingly, an output .7.16 mW/mm 2 (pulse duration: 50 ms) seemed to represent a threshold for excitation. Illumination outputs that were .7.16 mW/mm 2 resulted in capture of .95% of flashes. Below this threshold a sharp decline in success of pacing was noted, with ,5% of all flashes resulting in captured beats. The threshold-like phenomenon observed in the flash intensity (but not flash-duration) curve can also be appreciated in the strengthduration curves of the co-cultures. This graph is acquired by varying both illumination intensity and duration and plotting the minimal set of paired values required to achieve capture of all (100%) beats. Note in the example provided in Figure 3E that while small increments in pulse duration were required to compensate for a reduction in light intensity at the higher intensity values to yield 100% capture, significantly larger changes in pulse duration were required at lower intensity values. Finally, beyond a certain value (4.7 mW/mm 2 in this example) no further increments in pulse duration could compensate for the decrease in pulse intensity in order to achieve capture of all beats.
Optogenetics pacing of hESC-derived cardiomyocyte clusters
To verify that our optogenetics strategy could also be used to pace human cardiomyocytes, we repeated the stimulation studies in co-cultures consisting of hESC-derived cardiomyocyte tissue and ChR2-fibroblasts ( Figure 4A ). These studies verified that the engineered cells could reproducibly pace the human cardiomyocyte clusters at different stimulation frequencies. Notice in the example in Figure 4B , in which baseline contracting rate was extremely slow ( 2 beats/min), that the human cardiomyocytes could be optogenetically paced at rates of up to 80 flashes/min. In the second example ( Figure 4C) , beating frequency could be increased from 82 beats/min (darkness) to up to 190 beats/min following illumination. Optogenetics pacing was observed in 79% (33/42) of the different co-culture studies. In 60% of the co-cultures (25/42), we observed capture of 100% of the flashes, in another 19% (8/42) only partial capture (,100%) of the light impulses was found, while in rest of the co-cultures (9/42) optogenetics pacing could not be achieved.
Activation mapping in the co-cultures
We next aimed to characterize the electrical activation pattern of the optogenetically paced NRCMs co-cultures, to verify that the source of the new pacemaking activity was indeed the engineered cells. To this end, we focally seeded a cell cluster of ChR2-fibroblasts (eGFPexpressing cells at the top of the co-culture, Figure 5A ). In the same NRCMs cultures, we also seeded non-transfected control fibroblasts (eGFP-negative cells) at a different location (lower-corner of the MEA plate; not shown in Figure 5A ). We then applied diffused illumination to the entire co-culture targeting both types of fibroblast clusters. Figure 5B and C and Supplementary data online, Movie S2 display the resulting activation and propagation maps of the co-culture. Notice that the pacemaker area (red) during spontaneous beating (darkness) was located at the mid-right section of the co-culture with the wavefront spreading to activate the rest of the culture ( Figure 5B ). In contrast, application of blue-light illumination resulted in a shift in the location of the pacemaker area ( Figure 5C and Supplementary data online, Movie S2) to the area of the engineered ChR2-fibroblasts.
Multisite optogenetics pacing
In the experiments described above, despite a shift in pacemaker location, the overall activation time of the culture did not substantially change between spontaneous activity and optogenetics pacing ( Figure 5B and C ) . In the clinical situation, however, ventricular pacing from a single site may actually increase the total ventricular activation time when compared with normal conduction utilizing the His-Purkinje conduction system. Consequentially, conventional right-ventricular pacing may result in mechanical dyssynchronization and worsening of contractile performance. 22 To overcome this limitation, a biventricular pacing strategy has emerged in which the left ventricle is paced simultaneously from two sites (usually the septum and lateral wall). This CRT approach was eventually shown to lead to a clinical benefit also in a patient population with heart failure and impaired conduction even without a conventional indication for pacing. 23 To evaluate the feasibility of establishing an optogenetics-based CRT approach, we seeded cell clusters of ChR2-fibroblasts diffusely throughout the NRCMs cultures ( Figure 6A) . We hypothesized that following Optogenetics cardiac pacing diffused blue-light illumination, the culture will be activated simultaneously from multiple sites, significantly shortening total culture activation time and promoting synchronous contraction. Figure 6B and C provides examples of activation maps generated in such a co-culture during both spontaneous activity ( Figure 6B ) and following diffused bluelight illumination ( Figure 6C) . Notice that during spontaneous activity, electrical activation initiated from the native pacemaker area (red) in the lower-left area and then propagated to activate the rest of the tissue ( Figure 6B and Supplementary data online, Movie S3) with a total activation time of 196 ms. Following diffused blue-light illumination, the activation pattern of the co-culture markedly changed. Notice in Figure 6C and Supplementary data online, Movie S3 that electrical activation was initiated simultaneously from several different sites within the co-culture. This resulted in substantial shortening of the culture's total activation time (from 196 to 47 ms).
Multisite optogenetics pacing was associated with a significant reduction in the total activation time in all co-cultures studied (n ¼ 7, by an average of 71 + 7%, P , 0.05) when compared with spontaneous activation. We also adjusted the activation time of each co-culture to the area covered by the measuring electrodes in each plate. The logarithmic result of the calculated adjusted activation times is presented in Figure 6D . Note that the normalized activation time was markedly reduced during multisite optogenetics pacing in each individual culture (n ¼ 7) as well as the mean value for all cultures when compared with spontaneous activity (from 213 + 74 ms/mm 2 during spontaneous activity to 58 + 20 ms/mm 2 during multisite optogenetics pacing, P , 0.05).
Optogenetics pacing to synchronize conduction in a model of conduction block
Finally, we also evaluated the ability of the optogenetics pacing approach to restore synchronized conduction in a model of conduction block.
To this end, we cultured the NRCMs at a low density and then seeded the engineered ChR2-fibroblasts. In some of the co-cultures generated, we could identify the presence of conduction blocks with different NRCMs-clusters beating independently in a non-synchronized manner ( Figure 7) . Note that the electrical activity recorded from two electrodes (green and red electrodes in Figure 7A ) clearly identifies nonsynchronous activity ( Figure 7B) , with the NRCMs cell cluster at the top (green electrode) beating at a faster rate than the cardiomyocytes at the bottom of the culture (red electrode). Diffuse illumination (flashing cycle length of 450 ms) rapidly synchronized the electrical activity in the culture. Notice that the electrograms recorded from the green and red electrodes now became time locked ( Figure 7C ). were seeded in the upper part (green area) while control non-transfected fibroblasts (eGFP negative) were seeded on the bottom end. (B and C ) Activation maps generated during spontaneous culture activity (darkness, B) and during diffuse blue-light illumination. Note the shift in pacemaker location to the ChR2-fibroblasts area.
Bi-directional control of cardiac activity with optogenetics
We next attempted to determine whether a modified optogenetics approach could also be used to suppress cardiac excitability. To this end, we established fibroblasts that express both ChR2 and the hyperpolarizing light-sensitive proton pump ArchT 12 (ChR2/ArchT-fibroblasts).
To test the ability of these modified fibroblasts to either augment or suppress cardiac excitability, we co-cultured NRCMs with the ChR2/ ArchT-fibroblasts, which were seeded diffusely throughout the culture ( Figure 8A and C ). We next confirmed that the engineered cells continued to express both transgenes (ChR2-GFP and ArchT-dtTomato) throughout the experiment. Note in Figure 8B that the diffusely seeded engineered fibroblasts continued to express both light-sensitive proteins as evident by their combined eGFP (green cells in Figure 8B ) and dtTomato (orange cells in Figure 8C ) fluorescence. We next applied diffuse illumination to the co-cultures for 30 s using a 624 nm monochromatic light to activate the ArchT proton pump. As can be seen in Figure 8D , this resulted in complete suppression of the electrical activity throughout the culture. Such complete termination of electrical activity in the cultures was observed in 9 out of 11 of the cultures studied. Finally, to demonstrate the dual capabilities of the engineered cells, we applied flashes of blue light to activate the ChR2 channel and demonstrated the ability of the same cells to also optogentically pace the cultures at variable rates ( Figure 8E and F ) .
Discussion
Optogenetics is a new scientific discipline that utilizes light-sensitive proteins and specifically light-activated ion channels to selectively activate excitable cells by light. 6 -9 The most widely used protein in this emerging discipline has been ChR2, a non-selective light-sensitive cationic channel, initially identified in the green-alga Chlamydomonas.
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While algae use ChR2 to signal the presence of light and trigger their movement away or toward it, expression of this protein in neurons allows provoking light-triggered action potentials in these cells (even when embedded deep within the brain). Consequentially, the ability to apply precise perturbations of neural circuits by light has revolutionized neuroscience. 8, 9 Surprisingly, the use of similar optogenetics tools for non-neuronal application has not been explored until recently. 13 -15 In the current study, we continued to expand the potential use of optogenetics in the field of cardiac research. By overexpressing ChR2 in fibroblasts, which can couple electrically with neighbouring cardiomyocytes in an in vitro co-culture model, we demonstrated the feasibility of this approach for biological cardiac pacemaking and resynchronization therapy applications. In a similar manner, proof-of-concept studies utilizing engineered fibroblasts expressing the hyperpolarizing proton pump ArchT also revealed the feasibility of the optogenetics technology to also suppress cardiac electrical activity.
The majority of studies employing optogenetics tools have utilized viral vectors to deliver the transgene into the target tissue. While this strategy has proved useful for short-term applications in experimental neuroscience, clinical translation of this approach in the cardiac field may be hampered by some limitations. These include the inherent risks associated with the use of viral vectors, the inability to achieve longterm transgene expression in cardiac tissue and the inability to adequately control transgene expression levels within the cells, the number of transfected myocytes, and their spatial distribution.
An alternative approach that can overcome some of the aforementioned shortcomings of gene therapy may involve the use of genetically modified cell grafts that can be initially transfected ex vivo to express the desired properties. This may allow precise engineering and characterization of the modified cells prior to cell grafting, improved localizing of the therapeutic effect to the site of cell transplantation, and theoretically sustained long-term expression of the transgene. We and others have demonstrated the feasibility of this approach for modulating cardiactissue excitability by utilizing cell grafts (fibroblasts, HEK cells, or mesenchymal stem cells) engineered to express different ionic channels.
7,15,17,24 -27 The general hypothesis of this approach was that the engineered cells would couple with host cardiac tissue and affect myocardial electrophysiological properties by way of electrotonic interactions. Based on the type of current expressed, the grafted cells may either suppress (potassium channels) 17, 25 or augment (sodium channels, HCN-2 encoded pacemaker current (If), or ChR2) 15, 24, 26 cardiac excitability and conduction.
In the current study, we hypothesized that fibroblasts, engineered to express ChR2, can allow optogenetics pacing of cardiac tissue. A prerequisite for the success of such an approach is the presence of a significant light-induced inward current in the engineered cells, that the engineered cells form electrical connections with host cardiomyocytes, and that the electrotonic currents generated will be sufficient to depolarize coupled cardiomyocytes to threshold.
Our results support the fulfilment of the aforementioned requirements. Voltage clamp studies revealed a robust light-activated voltage-dependent inward current in the transfected fibroblasts, whose biophysical properties was consistent with previous reports. 15, 21 The
ChR2-fibroblasts were demonstrated to couple electrically with neighbouring cardiomyocytes and the resulting electrotonic currents transmitted from the engineered cells (following blue-light illumination) to the coupled cardiomyocytes were sufficient to induce a propagated action potential in the co-cultures; thus, confirming the ability of the coupled fibroblast-cardiomyocyte cells to serve as a light-activated pacemaker unit. We chose to use fibroblasts from an immortalize cell line (NIH-3T3) for this feasibility study because of the relative ease of engineering these cells to robustly express the ChR2 transgene, because of the ability to select and expand the engineered cells with the desired properties, and because of their proven ability to couple with NRCMs and to modify their electrical properties in this co-culture model. 17, 25, 26 Nevertheless, to advance the suggested approach beyond this proofof-concept in vitro study, primary cells should be utilized. The candidate cell types should have the necessary properties that will allow them to be harvested and expanded in an autologous manner, engineered to express the desired transgene, transplanted to the in vivo heart, and couple electrically with host cells to effectively modulate myocardial electrical properties.
Primary fibroblasts represent an attractive candidate for such a task and such cells were previously shown to couple and modify the electrical properties of cardiomyocytes in several in vitro studies. 28 -31 However, the ability of fibroblasts to form electrical connections with host cardiomyocyte also in the in vivo setting as suggested by some studies 32 -34 is still a matter of debate and may depend on the fibroblasts' activation state. 32, 35 Similarly, although the ChR2-fibroblasts were shown to optogenetically pace two types of cardiomyocytes (NRCMs and hESCderived cardiomyocytes), these cells have a relatively early-stage phenotype. Consequentially, the ability of the engineered cells to pace the adult heart tissue still needs to be demonstrated. The optogenetics pacemaker unit established displayed unique doseresponse properties. First, capture efficiency was affected by optogenetics flashing frequency. Three types of co-cultures could be observed with regards to their ability to follow rapid flashing frequencies (high, intermediate, and low responders). These difference may stem from a variety of reasons including the degree of electrical coupling (number of functional gap junctions) formed between the fibroblasts and the cardiomyocytes and between the cardiomyocytes themselves, the ratio between fibroblasts and cardiomyocytes number (both locally and on the whole-culture levels), the cardiomyocytes well-being, and by the inevitable replication of some non-ChR2-expressing fibroblasts in the culture. Importantly, all co-cultures could be effectively paced at physiological resting heart rates (,100 beats/min). Second, two distinct patterns of dose-response curves were obtained when altering the illumination parameters (duration and intensity). Interestingly, while a gradual decrease in the efficiency of optogenetics pacing was noted following gradual shortening of the impulse duration, the light-intensity dose-response curve showed a distinct threshold phenomenon.
The results of the current study suggest three different clinical scenarios in which optogenetics pacing could become a useful tool in the future. The first could be the use of transplanted ChR2-expressing cells (coupled with an implanted light source) for biological pacemaking as an alternative for electrotonic pacemakers. Work in the last decade resulted in a number of innovative cell therapy strategies for biological pacemaking. 2 -4 These included the implantation of stem cell-derived cardiomyocytes with pacemaker properties, 36 transplantation of cells genetically engineered to express the pacemaker current I f, 24,27 or most recently by reprogramming of working cardiomyocytes into pacemaker cells by transcription factors. 37 However, the use of such cells for continuous modulation of cardiac excitation may act as a double-edged sword since their activity may be totally autonomous, potentially resulting in pacemaker failure or alternatively leading to enhanced arrhythmogenticity. The use of externally controlled cells, as described in the current report, may potentially represent an advantage with regard to both safety and applicability. A second application may be the use of optogenetics pacing to restore rapid conduction in areas of conduction abnormalities. In the current study, we demonstrated the ability of the ChR2-fibroblasts to synchronize cardiomyocytes activity in a co-culture model of conduction block by the simultaneous light-induced activation of the non-coupled cardiomyocyte clusters. Since conduction abnormalities may facilitate reentrant arrhythmias, such an approach may potentially be beneficial also for prevention of tachyarrhythmias. The third application relates to the possible use of multisite optogenetics pacing as an improved CRT strategy. By scattering the transfected fibroblast-clusters throughout the culture, we were able to induce simultaneous activation of the NRCMs cultures from multiple different sites, resulting in a rapid and nearly synchronous activation of the entire culture. Consequentially, one could envision, in the future, the development of an optogenetics-based 'biological CRT approach' in which multiple cardiac sites could be activated simultaneously using a single diffuse light source. Importantly, the goal of multisite pacing in vivo would be not only to reduce activation time by simultaneous illumination (as demonstrated in the co-culture model) but also to achieve an ideal sequence of ventricular activation. Unfortunately, this question as well as other issues such as the presence and location of scarred and dyskinetic LV regions cannot be addressed in this in vitro model. In theory, however, the current technology has a unique potential to address the aforementioned challenges. This stems for the ability to initially map the LV electromechanical substrate, 38, 39 to design a potential therapeutic strategy, and then to control the exact locations where the engineered cells can be delivered and potentially also the desired sequence of activation (by using a number of light sources programmed to achieve predetermined illumination sequence). Nevertheless, although we believe that the results of the current in vitro study support the feasibility of the suggested optogenetics approaches for cardiac pacing and resynchronization, it should only be regarded as an initial proof-of-concept study. Clinical translation of such optogenetics pacing strategies would require overcoming many significant hurdles. These include the need to shift from the use of an immortalized fibroblast cell line in in vitro co-culture studies to the utilization of primary autologous cells in more clinically relevant in vivo models. For the latter, one would need to assure the prolonged survival of the transfected cells following transplantation, the continuous expression of the light-sensitive ion channels, and the ability of the engrafted cell to form electrotonic connections with host cardiomyocytes also in the intact heart. Importantly, any clinical application will require reinventing the cardiac pacemaker as we know it; creating a device capable of transmitting a predetermined amount of light into the myocardium. Such a device will probably be utilizing optical fibres instead of the traditional metallic wires. In addition, multisite optogenetics pacing will probably require the development of techniques to diffuse illumination onto a large area. Similarly, it is still not known whether blue-light illumination can sufficiently penetrate through cardiac tissue or blood to efficiently activate the engrafted cells from either an endocardial or epicardial approach. In this regard, it should be noted that next-generation light-activated channels are currently being developed, which will be sensitive to light sources with significantly better tissue penetrance characteristics (near infrared spectrum). Future studies should also determine whether a light-driven cardiac pacemaker is energetically efficient in comparison with conventional electronic pacemakers.
Finally, we also performed feasibility studies demonstrating the ability of the combined gene and cell therapy optogenetics strategy to suppress cardiac-tissue electrical activity through the expression and activation of the hyperpolarizing light-sensitive proton pump ArchT. Our results demonstrate the ability to 'silence' electrical activity following lightbased activation of this proton pump. This approach could potentially lead to the development of strategies aiming to treat different tachyarrhythmias (optogenetics-based functional 'molecular ablation' or 'molecular defibrillation' approaches). Moreover, the ability of the same cell to either augment or suppress cardiac excitability based on the type of light exposure may provide a unique tool for both experimental and clinical cardiology.
In summary, we describe the utilization of a combined cell and gene approach for optogenetics pacing and resynchronization. The current proof-of-concept study demonstrated the ability of the engineered cells to optogentically pace the cardiac cultures, to shorten the cultures' activation times through multisite optogenetics pacing, and to resynchronize areas with conduction block. As demonstrated with the use of ArchT, the same concepts could potentially be expanded to develop strategies that would lead to light-induced suppression (rather than excitation) of cardiac electrical activity; potentially leading to the development of novel therapeutic strategies for tachyarrhythmias. Nevertheless, clinical translation of these initial in vitro observations would require significant technological advancements as well as extensive future animal experimentation.
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